drugset / Trial / NCT02183168

Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis

NCT02183168

Phase 3 Completed 192 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

Study to assess the efficacy and safety of meloxicam suppository 15 mg once daily, meloxicam tablet 15 mg once daily compared with Indomethacin suppository (50 mg daily) in patients with ankylosing spondylitis

Timeline

Start
2001-07-01
Primary completion
2002-05-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Indomethacin Small molecule 50 mg Rectal
Subject Meloxicam Small molecule 15 mg Rectal